Provided by Tiger Trade Technology Pte. Ltd.

Gossamer Bio Inc.

0.3815
+0.036610.61%
Post-market: 0.3800-0.0015-0.39%17:55 EDT
Volume:14.96M
Turnover:5.51M
Market Cap:89.54M
PE:-0.51
High:0.3970
Open:0.3535
Low:0.3495
Close:0.3449
52wk High:3.87
52wk Low:0.3213
Shares:234.70M
Float Shares:211.00M
Volume Ratio:0.72
T/O Rate:7.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7455
EPS(LYR):-0.7455
ROE:-783.37%
ROA:-41.86%
PB:-0.73
PE(LYR):-0.51

Loading ...

Gossamer Bio Cut to Neutral From Overweight by Cantor Fitzgerald

Dow Jones
·
Mar 23

Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

TIPRANKS
·
Mar 23

Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

TIPRANKS
·
Mar 21

Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and Silexion Therapeutics (SLXN)

TIPRANKS
·
Mar 19

Levi & Korsinsky probes Gossamer Bio statements after PROSERA Phase 3 trial miss

Reuters
·
Mar 19

Gossamer Bio’s Seralutinib Future in Doubt After PROSERA Miss in PAH Raises FDA, Funding and Viability Risks

TIPRANKS
·
Mar 19

Portnoy Law Firm probes possible securities fraud at Gossamer Bio after 80.14% stock plunge

Reuters
·
Mar 18

Top News Today/Canada: Lululemon Appoints New Board Member; Fourth-Quarter Sales Rise

Dow Jones
·
Mar 18

CORRECTED-Gossamer Bio Q4 net loss widens

Reuters
·
Mar 18

Gossamer Bio Q4 net loss rises 43.01% to USD 47.24 million on R&D expenses up 35.5% to USD 48.94 million

Reuters
·
Mar 18

BRIEF-Gossamer Bio Q4 EPS USD -0.21

Reuters
·
Mar 18

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Mar 18

Gossamer Bio: Pauses Enrollment in Phase 3 Seranata Study in Ph-Ild While Co Evaluates Implications of Prosera Results

THOMSON REUTERS
·
Mar 18

Gossamer Bio: Co Implemented Reduction in Force to Align Resources With Near-Term Priorities

THOMSON REUTERS
·
Mar 18

Gossamer Bio Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
Mar 09

Gossamer Bio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 06

Levi & Korsinsky Investigates Gossamer Bio After PROSERA Phase 3 Trial Misses Endpoint

Reuters
·
Mar 05

Gossamer Bio Faces Investor Lawsuit After Phase 3 PROSERA Trial Miss

Reuters
·
Mar 05

Levi & Korsinsky Probes Gossamer Bio for Possible Securities Fraud

Reuters
·
Mar 04

Gossamer Bio, Inc. : Barclays Cuts to Underweight From Overweight

THOMSON REUTERS
·
Feb 25